Search

Your search keyword '"Pemo, C. F."' showing total 2 results
Start Over Author "Pemo, C. F."
2 results on '"Pemo, C. F."'

1. Improving adherence to highly active anti-retroviral therapy in Africa: the DREAM programme in Mozambique.

Author

Marazzi, M. C., Bartolo, M., Gialloreti, L. Emberti, Germano, P., Guidotti, G., Liotta, G., Lio, M. Magnano San, Mancinelli, S., Modolo, M. A., Narciso, P., Pemo, C. F., Scarcella, P., Tintisona, G., and Palombi, L.

Subjects
RETROVIRUS diseases, THERAPEUTICS, AIDS, PATIENTS
Abstract

Ensuring high levels of adherence to highly active anti-retroviral therapy (HAART) is a priority in treating people living with AIDS. This study reports the rates of adherence of patients served by DREAM (Drug Resource Enhancement against AIDS and Malnutrition) in the city of Matola, Mozambique. DREAM, an innovative programme tailored for Africa, was implemented by the Community of Sant'Egidio in August 2001. DREAM provides patients with anti-retroviral drugs and laboratory tests at no charge, and is based on a particular strategy of health education and organization of services designed for a population that is predominantly poor and has a low level of formal education. This study analyzes the adherence of 154 patients over a period of 6 months. In evaluating adherence, two indicators were used: (1) the percentage of appointments kept for check-ups, tests and the collection of medicine, and (2) the overall change in the patients' blood chemistry over the 6-month period. Of the 154 patients, 127 (82.5%) kept more than 90% of their appointments. Adherence to the programme was further confirmed by a relevant increase of hemoglobin levels and CD4 counts, and a significant decrease in the viral loads among the 154 patients. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

2. 48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: The OSCAR study

Author

Nozza, S., Pignataro, A. R., Laura Galli, Svicher, V., Alteri, C., Boeri, E., Ripa, M., Castagna, A., Sampaolo, M., Clementi, M., Pemo, C. F., Lazzarin, A., Nozza, Silvia, Pignataro, Angela Rosa, Galli, Laura, Svicher, Valentina, Alteri, Claudia, Boeri, Enzo, Ripa, Marco, Castagna, Antonella, Sampaolo, Michela, Clementi, Massimo, Perno, Carlo Federico, and Lazzarin, Adriano

Subjects
Adult, Male, Genotype, Anti-HIV Agents, Genotypic tropism assay, HIV Infections, Drug Administration Schedule, Settore MED/07, Maraviroc, Failing patients, Cyclohexanes, Cyclohexane, Trofile, Humans, HIV Infection, Treatment Failure, Failing patient, Anti-HIV Agent, Female, HIV-1, Middle Aged, Triazoles, Viral Tropism, Settore MED/07 - Microbiologia e Microbiologia Clinica, Triazole, Human
Abstract

This study assessed the 48-week efficacy of an antiretroviral therapy including maraviroc following the assessment of co-receptor tropism by use of Geno2Pheno algorithm or the Trofile phenotypic assay in failing treatment-experienced HIV-1 patients. This was a multicenter, randomized, open-label, non-inferiority trial. Treatment-experienced subjects with HIV-RNA ≥500 copies/mL were randomized (1:1) to undergo co-receptor tropism testing by the Geno- 2Pheno algorithm (with a false positive rate >10%) or the Trofile assay before starting a new antiretroviral treatment which included maraviroc. The primary endpoint was the 48 week proportion of patients with treatment success (TS). Intention-to-treat analyses are also reported. One hundred and fifty-five experienced patients were analysed: 77 patients in the Trofile arm and 78 in the Genotype arm. The 48-week proportion of TS was 87% in the Trofile arm and 89% in the Genotype arm (difference: 1.5%, 95%CI: -8.9% to 11.8%) suggesting non-inferiority. In the Trofile arm, 10 patients had treatment failure: 5 viral rebound, 5 discontinuations. In the Genotype arm, 9 patients had treatment failure: 7 viral rebound, 2 lost to follow-up. CD4+ significantly increased from baseline to week 48 in both arms. 48-week treatment success was similar for maraviroc-including therapy prescribed following the Trofile phenotypic assay or Geno2Pheno algorithm.

Catalog

Books, media, physical & digital resources
See catalog results